Erasca, Inc. Common Stock
ERASErasca, Inc. is a biotechnology company focused on developing targeted therapies for cancer treatment. The company specializes in utilizing genomic and proteomic data to identify and develop personalized medicines for patients with various types of cancer. It aims to advance precision oncology through innovative drug discovery and development strategies.
Company News
Erasca, Inc., a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers, announced the pricing of an upsized public offering of 22.5 million shares at $10.00 per share, generating $225 million in gross proceeds. The offering is expected to close on January 23, 2026, with proceeds to be used for R&D of product candidat...
The precision oncology market is projected to grow from $110 billion to $225.65 billion by 2032, driven by Big Pharma's race to acquire registration-ready assets ahead of a $170 billion patent cliff through 2030. Several biotech companies are advancing promising clinical programs: Oncolytics Biotech strengthened its leadership team for pelareorep...
Clinical-stage biotech Erasca reported Q2 2025 results, highlighting reduced operating expenses and progress in two RAS-pathway cancer therapy clinical trials entering Phase 1, while maintaining a strong cash position to fund operations through 2028.
Erasca, a clinical-stage precision oncology company, announced the advancement of its RAS-targeting franchise, with IND clearance for ERAS-0015 and IND submission for ERAS-4001, both ahead of schedule. The company expects to report Phase 1 monotherapy data for both programs in 2026 and has a projected cash runway of more than 3 years.
Erasca, Inc. (ERAS), a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers, announced its participation in the Guggenheim Securities SMID Cap Biotech Conference, where management will present and hold one-on-one investor meetings.
